You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Shares of Illumina fell in afternoon trading on the Nasdaq following a brief rise after the market open.
A Lund University-led team developed two methylation risk scores to predict which patients would or would not respond to treatment and experience side effects.
Genomic and epigenomic data suggest it may be possible to target an FGFR fusion found in open chromatin in a subset of adenosquamous carcinoma of the pancreas tumors.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
The company recently had a second pre-submission with FDA and expects to begin a prospective trial of its test in the second half of this year.
The Oslo-based company plans to develop a test that can identify high-risk individuals based on an epigenetic signature.
Dogs age more rapidly in their early years but then age more slowly later on, a DNA methylome analysis found, changing how dogs' ages are translated to human ages.
The company recently presented results from its Aurora assay for multi-cancer screening and plans to launch a $100 test for the US and Chinese markets.
Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets.
The Oxford, UK-based firm announced the closure of a seed financing round this week as well as plans to develop a methylation-based blood test for early-stage cancer detection.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.